FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2464378224> ?p ?o ?g. }

• W2464378224 endingPage "411" @default.
• W2464378224 startingPage "402" @default.
• W2464378224 abstract "Background: Abnormal activation of the Wnt/β-catenin signaling pathway increases survivin expression that is involved in hepatocarcinogenesis. Therefore, downregulation of survivin may provide an attractive strategy for treatment of hepatocellular carcinoma. In this regard, little is known about the anticancer effects of prodigiosin isolated from cell wall of Serratia marcescens on the survivin expression and induction of apoptosis in hepatocellular carcinoma cells. Methods: Human hepatocellular carcinoma (HepG2) cells were treated with 100-, 200-, 400-, and 600-nM prodigiosin after which morphology of cells, cell number, growth inhibition, survivin expression, caspase-3 activation, and apoptotic rate were evaluated by inverted microscope, hemocytometer, MTT assay, RT-PCR, fluorometric immunosorbent enzyme assay, and flow cytometric analysis, respectively. Results: Prodigiosin changed morphology of cells to apoptotic forms and disrupted cell connections. This compound significantly increased growth inhibition rate and decreased metabolic activity of HepG2 cells in a dose- and time-dependent manner. After 24-, 48-, and 72-h treatments with prodigiosin at concentrations ranging from 100 nM to 600 nM, growth inhibition rates were measured to be 1.5–10%, 24–47.5%, and 55.5–72.5%, respectively, compared to untreated cells. At the same conditions, metabolic activities were measured to be 91–83%, 74–53%, and 47–31% for indicated concentrations of prodigiosin, respectively, compared to untreated cells. We also found that treatment of HepG2 cells for 48 h decreased significantly cell number and survivin expression and increased caspase-3 activation in a dose-dependent manner. Specifically, treatment with 600-nM prodigiosin resulted in 77% decrease in cell number, 88.5% decrease in survivin messenger RNA level, and 330% increase in caspase-3 activation level compared to untreated cells. An increase in the number of apoptotic cells (late apoptosis) ranging from 36.9% to 97.4% was observed with increasing prodigiosin concentrations. Conclusion: From our data, prodigiosin is an attractive compound that turns the profile of high-level survivin expression in hepatocellular carcinoma cells into that of normal cells and may provide a novel approach to the hepatocellular carcinoma-targeted therapy." @default.
• W2464378224 created "2016-07-22" @default.
• W2464378224 creator A5017907765 @default.
• W2464378224 creator A5031639540 @default.
• W2464378224 creator A5064718149 @default.
• W2464378224 date "2016-06-22" @default.
• W2464378224 modified "2023-09-26" @default.
• W2464378224 title "Targeting survivin with prodigiosin isolated from cell wall of <i>Serratia marcescens</i> induces apoptosis in hepatocellular carcinoma cells" @default.
• W2464378224 cites W175129250 @default.
• W2464378224 cites W1966896726 @default.
• W2464378224 cites W1971615566 @default.
• W2464378224 cites W1975515453 @default.
• W2464378224 cites W1979618048 @default.
• W2464378224 cites W1981250654 @default.
• W2464378224 cites W1982383186 @default.
• W2464378224 cites W1984722635 @default.
• W2464378224 cites W1987292110 @default.
• W2464378224 cites W1990563353 @default.
• W2464378224 cites W1992129618 @default.
• W2464378224 cites W2000556896 @default.
• W2464378224 cites W2008181517 @default.
• W2464378224 cites W2018642147 @default.
• W2464378224 cites W2026216334 @default.
• W2464378224 cites W2029368695 @default.
• W2464378224 cites W2044843189 @default.
• W2464378224 cites W2060107083 @default.
• W2464378224 cites W2064580048 @default.
• W2464378224 cites W2070080310 @default.
• W2464378224 cites W2083860222 @default.
• W2464378224 cites W2123003149 @default.
• W2464378224 cites W2132299300 @default.
• W2464378224 cites W2133619324 @default.
• W2464378224 cites W2143981899 @default.
• W2464378224 cites W2153383148 @default.
• W2464378224 cites W2161818053 @default.
• W2464378224 cites W2172027841 @default.
• W2464378224 cites W226212453 @default.
• W2464378224 cites W2917837889 @default.
• W2464378224 cites W3149376927 @default.
• W2464378224 doi "https://doi.org/10.1177/0960327116651122" @default.
• W2464378224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27334973" @default.
• W2464378224 hasPublicationYear "2016" @default.
• W2464378224 type Work @default.
• W2464378224 sameAs 2464378224 @default.
• W2464378224 citedByCount "25" @default.
• W2464378224 countsByYear W24643782242017 @default.
• W2464378224 countsByYear W24643782242018 @default.
• W2464378224 countsByYear W24643782242019 @default.
• W2464378224 countsByYear W24643782242020 @default.
• W2464378224 countsByYear W24643782242021 @default.
• W2464378224 countsByYear W24643782242022 @default.
• W2464378224 crossrefType "journal-article" @default.
• W2464378224 hasAuthorship W2464378224A5017907765 @default.
• W2464378224 hasAuthorship W2464378224A5031639540 @default.
• W2464378224 hasAuthorship W2464378224A5064718149 @default.
• W2464378224 hasConcept C104317684 @default.
• W2464378224 hasConcept C1491633281 @default.
• W2464378224 hasConcept C153911025 @default.
• W2464378224 hasConcept C185592680 @default.
• W2464378224 hasConcept C190283241 @default.
• W2464378224 hasConcept C2775975398 @default.
• W2464378224 hasConcept C2776309202 @default.
• W2464378224 hasConcept C2779337610 @default.
• W2464378224 hasConcept C2780783641 @default.
• W2464378224 hasConcept C502942594 @default.
• W2464378224 hasConcept C547475151 @default.
• W2464378224 hasConcept C55493867 @default.
• W2464378224 hasConcept C62112901 @default.
• W2464378224 hasConcept C86803240 @default.
• W2464378224 hasConceptScore W2464378224C104317684 @default.
• W2464378224 hasConceptScore W2464378224C1491633281 @default.
• W2464378224 hasConceptScore W2464378224C153911025 @default.
• W2464378224 hasConceptScore W2464378224C185592680 @default.
• W2464378224 hasConceptScore W2464378224C190283241 @default.
• W2464378224 hasConceptScore W2464378224C2775975398 @default.
• W2464378224 hasConceptScore W2464378224C2776309202 @default.
• W2464378224 hasConceptScore W2464378224C2779337610 @default.
• W2464378224 hasConceptScore W2464378224C2780783641 @default.
• W2464378224 hasConceptScore W2464378224C502942594 @default.
• W2464378224 hasConceptScore W2464378224C547475151 @default.
• W2464378224 hasConceptScore W2464378224C55493867 @default.
• W2464378224 hasConceptScore W2464378224C62112901 @default.
• W2464378224 hasConceptScore W2464378224C86803240 @default.
• W2464378224 hasIssue "4" @default.
• W2464378224 hasLocation W24643782241 @default.
• W2464378224 hasLocation W24643782242 @default.
• W2464378224 hasOpenAccess W2464378224 @default.
• W2464378224 hasPrimaryLocation W24643782241 @default.
• W2464378224 hasRelatedWork W2185175380 @default.
• W2464378224 hasRelatedWork W2356428767 @default.
• W2464378224 hasRelatedWork W2358161411 @default.
• W2464378224 hasRelatedWork W2361455118 @default.
• W2464378224 hasRelatedWork W2362964312 @default.
• W2464378224 hasRelatedWork W2374215182 @default.
• W2464378224 hasRelatedWork W2383691845 @default.
• W2464378224 hasRelatedWork W2389001919 @default.
• W2464378224 hasRelatedWork W2439569490 @default.
• W2464378224 hasRelatedWork W879645222 @default.

• next